Pfizer ends phase 2 trial for lymphoma drug from Trillium acquisition

6 days ago 1

• Healthcare

georgeclerk

• Citing recruitment problems, Pfizer has ended a phase 2 trial of maplirpacept, a candidate targeting CD47 that the drug giant obtained in August 2021 as part of its $2.26B acquisition of Trillium Therapeutics.
• "The trial terminated due to the inability

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. Pfizer ends phase 2 trial for lymphoma drug from Trillium acquisition